Stock Traders Buy High Volume of Kiniksa Pharmaceuticals International Call Options (NASDAQ:KNSA)

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) saw some unusual options trading on Tuesday. Stock traders acquired 5,003 call options on the stock. This is an increase of approximately 1,047% compared to the typical daily volume of 436 call options.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 50,490 shares of the company’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $38.87, for a total value of $1,962,546.30. Following the completion of the transaction, the chief accounting officer owned 27,046 shares of the company’s stock, valued at $1,051,278.02. This represents a 65.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Sanj K. Patel sold 97,390 shares of the business’s stock in a transaction dated Wednesday, October 22nd. The stock was sold at an average price of $38.83, for a total value of $3,781,653.70. Following the sale, the chief executive officer owned 111,794 shares in the company, valued at approximately $4,340,961.02. This trade represents a 46.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 507,828 shares of company stock worth $19,544,025 over the last three months. 53.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nuveen LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth about $16,992,000. Arrowstreet Capital Limited Partnership acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $20,349,000. Qube Research & Technologies Ltd boosted its holdings in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after acquiring an additional 653,236 shares in the last quarter. Acadian Asset Management LLC grew its stake in Kiniksa Pharmaceuticals International by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock valued at $22,961,000 after acquiring an additional 651,700 shares during the period. Finally, Rubric Capital Management LP increased its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after acquiring an additional 526,567 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

KNSA has been the subject of several recent research reports. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Wedbush reiterated an “outperform” rating and issued a $48.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday. Finally, Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $52.00.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock opened at $40.59 on Thursday. Kiniksa Pharmaceuticals International has a fifty-two week low of $17.82 and a fifty-two week high of $42.98. The stock has a 50 day simple moving average of $39.35 and a two-hundred day simple moving average of $33.77. The company has a market cap of $3.08 billion, a P/E ratio of 90.20 and a beta of 0.02.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). The company had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The business’s quarterly revenue was up 61.2% compared to the same quarter last year. During the same period last year, the business earned ($0.18) EPS. On average, research analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.